Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANF-RHO
- Development stage
- Unknown
- Lead developer
- Prolong Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ANF-RHO is a pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF) developed by Prolong Pharmaceuticals. It is being investigated for the prophylactic treatment of chemotherapy-induced neutropenia in non-metastatic breast cancer patients and for the treatment of chronic neutropenia. The drug is administered via subcutaneous injection.
- Brand names
- ANF-RHO™
- Other names
- ANF-Rho
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on ANF-RHO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANF-RHO.